^
    Back
    Association details:
    Biomarker:BRCA1 mutation
    Cancer:Triple Negative Breast Cancer
    Drug:Zejula (niraparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Peritoneal Cancer)
    New
    Excerpt:
    ZEJULA is a poly(ADP-ribose) polymerase (PARP) inhibitor indicated:...for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either:...a deleterious or suspected deleterious BRCA mutation...
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Niraparib in Tumors Metastatic to the CNS

    Excerpt:
    ...- Diagnosis of triple negative breast cancer or ovarian cancer, or any cancer histology with the presence of alteration in BRCA1, BRCA2, PARP metabolism, DNA repair pathways and HRD (homologous recombination deficiency) genes in the metastatic site as described in Section 9.2 using a CLIA-certified assay....
    Trial ID:
    NCT04992013
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-II 2020
    Title:

    Abstract 3026: Evaluation of brain pharmacokinetics (PK) and tumor growth inhibition of PARP inhibitors in mouse xenograft models using semi-mechanistic PK/pharmacodynamic (PD) modeling

    Published date:
    05/15/2020
    Excerpt:
    However, rucaparib and niraparib demonstrated antitumor efficacy in a BRCA1-mutant, intracranial, TNBC mouse model.
    DOI:
    10.1158/1538-7445.AM2020-3026
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Neurooncol Adv
    Title:

    Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models

    Published date:
    06/04/2019
    Excerpt:
    Niraparib penetrates intracranial tumor tissues in mouse models of TNBC with impressive single-agent efficacy in BRCA-mutant MDA-MB-436.
    DOI:
    10.1093/noajnl/vdz005
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Neuro Oncol
    Title:

    Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models

    Excerpt:
    Daily niraparib increased median survival and decreased tumor burden in the BRCA-mutant MDA-MB-436 model...Niraparib penetrates intracranial tumor tissues in mouse models of TNBC with impressive single-agent efficacy in BRCA-mutant MDA-MB-436.
    DOI:
    https://doi.org/10.1093/noajnl/vdz005